CardioExchange Archive

February 11th, 2013

Selections from Richard Lehman’s Literature Review: February 11th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the effect of ramipril on walking times and quality of life among those with PAD and intermittent claudication, genetic associations with valvular calcification and aortic stenosis, and more.

---

August 2nd, 2012

DES in Patients at Low Risk for TVR: Is the Benefit Worth the Cost? (Part III)

John Spertus, MD, MPH, Robert W. Yeh, MD MSc MBA, Richard A. Lange, MD, MBA and L. David Hillis, MD

In a recent article in Archives of Internal Medicine, researchers performed an analysis of current use of drug-eluting stents (DES) in patients at various levels of risk for target-vessel revascularization (TVR), and estimated the cost and clinical outcomes of using BMS rather than DES in patients at low risk (see News). To gauge reaction to […]

---

July 27th, 2012

DES in Patients at Low Risk for TVR: Is the Benefit Worth the Cost? (Part II)

Richard A. Lange, MD, MBA, L. David Hillis, MD and Patrick Serruys, MD, PhD

In a recent article in Archives of Internal Medicine, researchers performed an analysis of current use of drug-eluting stents (DES) in patients at various levels of risk for target-vessel revascularization (TVR), and estimated the cost and clinical outcomes of using BMS rather than DES in patients at low risk (see News). To gauge reaction to […]

---

July 25th, 2012

DES in Patients at Low Risk for TVR: Is the Benefit Worth the Cost? (Part I)

Gregg W Stone, MD, John A. Bittl, M.D., David Kandzari, MD, Richard A. Lange, MD, MBA and L. David Hillis, MD

In a recent article in Archives of Internal Medicine, researchers performed an analysis of current use of drug-eluting stents (DES) in patients at various levels of risk for target-vessel revascularization (TVR), and estimated the cost and clinical outcomes of using BMS rather than DES in patients at low risk (see News). To gauge reaction to […]

---

July 10th, 2012

Drug-Eluting Stents Often Used in Patients at Low Risk for Restenosis

Larry Husten, PHD

The chief advantage of drug-eluting stents (DES) over bare-metal stents is that they significantly reduce the risk for restenosis. The chief disadvantages of DES are their greater cost and the requirement for prolonged dual antiplatelet therapy after implantation. In a study published in the Archives of Internal Medicine,  Amit Amin and colleagues analyzed data from 1.5 million […]

---